PD-1/PD-L1 Inhibitors plus Chemotherapy Versus Chemotherapy Alone for Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

• Published in: Cancers 2023-11, Vol.15 (21), p.5143
• Main Authors: Pasqualotto, Eric, Moraes, Francisco Cezar Aquino de, Chavez, Matheus Pedrotti, Souza, Maria Eduarda Cavalcanti, Rodrigues, Anna Luíza Soares de Oliveira, Ferreira, Rafael Oliva Morgado, Lopes, Lucca Moreira, Almeida, Artur Menegaz de, Fernandes, Marianne Rodrigues, Santos, Ney Pereira Carneiro dos
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Analysis; Apoptosis; Bias; Cancer; Cancer therapies; Care and treatment; Cell death; Chemotherapy; Citation management software; Clinical trials; Crizotinib; Health aspects; Hypothyroidism; Immunotherapy; Kinases; Ligands; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Lymphatic system; Meta-analysis; Metastases; Metastasis; Mortality; Neutrophils; Non-small cell lung carcinoma; Patients; PD-1 protein; PD-L1 protein; Small cell lung carcinoma; Surgery; Systematic review
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15215143

Background: The benefit of adding programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors to the treatment of early-stage non-small cell lung cancer (NSCLC), both neoadjuvant therapy (NAT) and adjuvant therapy (AT), is not yet fully elucidated. Methods: We searched PubMed, Embase, and Cochrane databases for randomized controlled trials (RCT) that investigated PD-1/PD-L1 inhibitors plus chemotherapy for resectable stage NSCLC. We computed hazard ratios (HRs) or odds ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs). Results: A total of seven RCTs comprising 3915 patients with resectable stage NSCLC were randomized to chemotherapy with or without PD-1/PD-L1 inhibitors as NAT or AT. As NAT, the PD-1/PD-L1 inhibitors plus chemotherapy group demonstrated significantly improved overall survival (HR 0.66; 95% CI 0.51–0.86) and event-free survival (HR 0.53; 95% CI 0.43–0.67) compared with the chemotherapy alone group. There was a significant increase in favor of the PD-1/PD-L1 inhibitors plus chemotherapy group for major pathological response (OR 6.40; 95% CI 3.86–10.61) and pathological complete response (OR 8.82; 95% CI 4.51–17.26). Meanwhile, as AT, disease-free survival was significant in favor of the PD-1/PD-L1 inhibitors plus chemotherapy group (HR 0.78; 95% CI 0.69–0.90). Conclusions: In this comprehensive systematic review and meta-analysis of RCTs, the incorporation of PD-1/PD-L1 inhibitors alongside chemotherapy offers a promising prospect for reshaping the established treatment paradigms for patients diagnosed with resectable stages of NSCLC. Moreover, our analyses support that neoadjuvant administration with these agents should be encouraged, in light of the fact that it was associated with an increased survival and pathological response, at the expense of a manageable safety profile.